ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FDMT 4D Molecular Therapeutics Inc

23.63
-0.78 (-3.20%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
4D Molecular Therapeutics Inc NASDAQ:FDMT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.78 -3.20% 23.63 23.56 25.00 24.38 23.50 24.05 365,641 21:57:40

4DMT to Participate in Upcoming Investor Conference

07/05/2024 1:00pm

GlobeNewswire Inc.


4D Molecular Therapeutics (NASDAQ:FDMT)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more 4D Molecular Therapeutics Charts.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May. Members of the management team will also be available for one-on-one meetings.

Bank of America Health Care Conference 2024

Presentation Date:Tuesday, May 14, 2024
Presentation Time:3:40 p.m. PT / 6:40 p.m. ET
Webcast Link:Webcast

Archived copies of the webcasts will be available for up to one year by visiting the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our product design, development, and manufacturing engine help us efficiently create and advance our diverse product pipeline with the goal of revolutionizing medicine with potential curative therapies for millions of patients. Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases in ophthalmology, pulmonology, and cardiology. In addition, 4DMT is also advancing programs in CNS through a gene editing partnership. 4D Molecular Therapeutics™, 4DMT®, 4D®, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Contacts:

Media:

Katherine SmithInizio Evoke CommsKatherine.Smith@inizioevoke.com

Investors:

Julian PeiHead of Investor Relations and Corporate CommunicationsInvestor.Relations@4DMT.com

1 Year 4D Molecular Therapeutics Chart

1 Year 4D Molecular Therapeutics Chart

1 Month 4D Molecular Therapeutics Chart

1 Month 4D Molecular Therapeutics Chart

Your Recent History

Delayed Upgrade Clock